GHRP-6 10mg

Research Disclaimer & Introduction

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide supplied as a lyophilized powder for laboratory investigation. This product is intended exclusively for qualified researchers conducting in vitro or in vivo studies in approved laboratory settings. Biosim Peptides does not condone or authorize any use of this compound outside of controlled research environments. By purchasing this product, the researcher certifies that they are qualified to handle research peptides and will comply with all applicable laws, regulations, and institutional guidelines.

GHRP-6 is a member of the growth hormone secretagogue (GHS) family — synthetic peptides engineered to stimulate the release of growth hormone (GH) from the anterior pituitary gland. First synthesized by Cyril Y. Bowers and colleagues in the mid-1980s, GHRP-6 is composed of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) and acts as a potent ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHS-R1a). Its dual action — directly stimulating pituitary somatotrophs while also amplifying endogenous growth hormone-releasing hormone (GHRH) signaling — makes it a foundational tool in neuroendocrine research. Investigators study GHRP-6 for its effects on the GH/IGF-1 axis, appetite regulation, gastric motility, and metabolic signaling pathways. This product page provides a comprehensive overview of GHRP-6’s molecular properties, mechanism of action, research applications, key published studies, and essential handling protocols.

Molecular Overview

GHRP-6 (CAS: 87616-84-0) is a hexapeptide with the primary sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ and a molecular weight of 873.01 g/mol. The peptide features a C-terminal amide group that enhances metabolic stability by reducing susceptibility to carboxypeptidase degradation. Two D-amino acid residues — D-tryptophan at position 2 and D-phenylalanine at position 5 — confer significant resistance to proteolytic cleavage, extending the peptide’s functional half-life in biological matrices relative to all-L-amino acid peptides. The inclusion of D-amino acids also constrains the peptide’s conformational flexibility, favoring specific secondary structures that are critical for high-affinity receptor engagement.

The N-terminal histidine residue is vital for biological activity; alanine substitution at this position results in near-complete loss of GH-releasing activity in pituitary cell assays. The tryptophan residues at positions 2 and 4 contribute to hydrophobic interactions within the GHS-R1a binding pocket, while the C-terminal lysine amide participates in electrostatic interactions with receptor residues. GHRP-6 is soluble in water (≥1 mg/mL), physiological saline, and phosphate-buffered saline (PBS), and should be stored at -20°C in lyophilized form, protected from light and moisture. Under these conditions, the lyophilized powder remains stable for up to 24 months.

GHRP-6 belongs to a broader class of synthetic GH-releasing peptides that includes GHRP-1, GHRP-2, hexarelin, and ipamorelin. Compared to these structural analogs, GHRP-6 exhibits a balanced pharmacological profile: it demonstrates strong GH-releasing potency, moderate appetite-stimulatory effects mediated through central ghrelinergic pathways, and a well-characterized safety record in preclinical models spanning over three decades of published research.

Mechanism of Action

GHRP-6 exerts its biological effects primarily through agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor (GPCR) that was first cloned and characterized by Howard and colleagues in 1996 (PMID: 8940206). The GHS-R1a is highly expressed in the arcuate nucleus and ventromedial hypothalamus, the anterior pituitary gland, and peripheral tissues including the gastrointestinal tract, pancreas, and adipose tissue.

At the pituitary level, GHRP-6 binds directly to GHS-R1a on somatotroph cells, activating the G_q/11-phospholipase C signaling cascade. This triggers inositol trisphosphate (IP₃)-mediated release of calcium from intracellular stores and subsequent activation of protein kinase C (PKC). The resulting rise in intracellular calcium drives the exocytosis of growth hormone-containing secretory granules. Critically, GHRP-6’s action at the pituitary is synergistic with GHRH: while GHRH activates the G_s-adenylyl cyclase-cAMP-PKA pathway, GHRP-6’s G_q-coupled signaling depolarizes somatotrophs and sensitizes them to GHRH. When administered together, GHRP-6 and GHRH produce a GH release response far exceeding the sum of their individual effects — a hallmark of the GHS/GHRH synergy that is a defining feature of this peptide class (PMID: 7593426).

At the hypothalamic level, GHRP-6 activates GHS-R1a-expressing neurons in the arcuate nucleus, stimulating the release of GHRH into the hypophyseal portal circulation while simultaneously suppressing somatostatin tone. This dual hypothalamic mechanism amplifies GH secretion beyond what direct pituitary stimulation alone would produce. Furthermore, GHRP-6 mimics the orexigenic actions of ghrelin — the endogenous ligand for GHS-R1a discovered by Kojima and colleagues (PMID: 9467543) — by activating neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus. This central appetite-stimulatory effect is one of the distinguishing features of GHRP-6 compared to more selective GHS compounds such as ipamorelin, which shows relatively less activation of feeding circuits.

Peripherally, GHRP-6 influences gastric motility and emptying through vagal afferent signaling and local enteric GHS-R1a activation. The peptide also modulates insulin secretion and glucose homeostasis through GHS-R1a expressed on pancreatic islet cells, a property that has generated significant interest in metabolic disease research.

Research Applications

GHRP-6 is employed across a broad range of preclinical research domains, reflecting the wide tissue distribution of the GHS-R1a receptor and the peptide’s multifaceted pharmacology. Key research application areas include:

Neuroendocrinology & Growth Hormone Axis Research. GHRP-6 is a standard tool for investigating the regulation of the GH/IGF-1 axis in rodent and large-animal models. Researchers use GHRP-6 to probe the signaling crosstalk between GHRH, somatostatin, and ghrelin pathways, to assess pituitary somatotroph responsiveness under various physiological and pathological conditions, and to study feedback mechanisms involving IGF-1 at the hypothalamic and pituitary levels (PMID: 8621038).

Appetite Regulation & Energy Homeostasis. The orexigenic properties of GHRP-6 make it a valuable tool for studying central feeding circuits. In rodent models, GHRP-6 administration increases food intake, meal frequency, and body weight — effects mediated by NPY/AgRP neuronal activation and downstream melanocortin system modulation. These studies are relevant to understanding cachexia, eating disorders, and metabolic wasting syndromes (PMID: 10844587).

Gastrointestinal Physiology. GHRP-6’s effects on gastric acid secretion, gastric emptying, and intestinal motility are studied in models of gastroparesis, postoperative ileus, and functional dyspepsia. The peptide’s ability to accelerate gastric emptying through vagal cholinergic pathways is one of the earliest characterized peripheral actions of the GHS family.

Cardiovascular Research. GHS-R1a receptors are expressed in cardiac tissue, and GHRP-6 has been investigated for its effects on cardiac contractility, left ventricular function, and vascular tone in experimental models of heart failure. Studies suggest that GHRP-6 may exert cardioprotective effects independent of GH/IGF-1 elevation, potentially through direct GHS-R1a signaling in cardiomyocytes.

Metabolic & Glucose Homeostasis Research. GHS-R1a signaling influences insulin secretion, insulin sensitivity, and lipid metabolism. Researchers study GHRP-6 in the context of obesity, type 2 diabetes, and metabolic syndrome to elucidate the interplay between the GH axis and metabolic regulation.

Aging & Sarcopenia Research. The age-related decline in GH secretion (somatopause) and its contribution to sarcopenia, bone loss, and altered body composition is a significant research focus. GHRP-6 is used to study whether pharmacological restoration of GH pulsatility can mitigate age-related physiological decline in appropriate preclinical models.

Key Published Studies

The scientific literature on GHRP-6 and related GH secretagogues spans more than three decades. The following studies represent seminal contributions to the understanding of GHRP-6 pharmacology and mechanism of action:

Bowers et al. (1995) — In Vitro and In Vivo Activity. Published in Endocrinology (PMID: 7593426), this foundational study characterized GHRP-6’s ability to stimulate GH release from primary rat pituitary cell cultures. The authors demonstrated that GHRP-6 acts through a receptor and signaling pathway distinct from that of GHRH, establishing the existence of a previously unrecognized GHS receptor system. The synergistic interaction between GHRP-6 and GHRH was quantitatively characterized for the first time.

Howard et al. (1996) — GHS Receptor Cloning. Published in Science (PMID: 8940206), this landmark paper reported the cloning and functional expression of the growth hormone secretagogue receptor (GHS-R1a) from human pituitary and hypothalamus. The identification of GHS-R as an orphan GPCR at the time of its cloning paved the way for the subsequent discovery of ghrelin as its endogenous ligand and provided the molecular framework for understanding GHRP-6’s mechanism of action.

Kojima et al. (1999) — Discovery of Ghrelin. Published in Nature (PMID: 9467543), this study identified ghrelin as the endogenous ligand for the GHS-R. The authors demonstrated that ghrelin, a 28-amino acid peptide with a unique n-octanoyl modification at Ser3, is produced primarily in the stomach and is a potent stimulator of GH release. This discovery transformed the understanding of GHRP-6 pharmacology, reclassifying GHRP-6 and its analogs as ghrelin mimetics.

Chapman et al. (1996) — GH/IGF-1 Axis Stimulation. Published in the Journal of Clinical Endocrinology & Metabolism (PMID: 8621038), this study characterized the effects of chronic GHRP administration on the GH/IGF-1 axis. The investigators demonstrated that repeated GHRP administration elevates circulating IGF-1 levels, confirming that GHRP-induced GH pulses are physiologically relevant and capable of activating downstream anabolic signaling cascades.

Takaya et al. (2000) — Ghrelin and GH Release in Humans. Published in JCEM (PMID: 11078470), this study validated that ghrelin strongly stimulates GH release in human subjects, demonstrating a dose-dependent effect and confirming the translational relevance of the GHS-R signaling system. The findings underscored the importance of synthetic ghrelin mimetics like GHRP-6 for understanding human GH regulation.

Wren et al. (2000) — Ghrelin and Appetite. Published in Endocrinology (PMID: 10844587), this study was among the first to demonstrate that peripheral and central ghrelin administration increases food intake and body weight in rodents. The findings are directly relevant to GHRP-6 research, as GHRP-6’s orexigenic effects are mediated through the same GHS-R1a signaling pathways that ghrelin engages to stimulate appetite.

Bowers (1998) — Comprehensive Review. Published in Cellular and Molecular Life Sciences (PMID: 9141532), this authoritative review by the discoverer of GHRP-6 provides a comprehensive overview of the development, structure-activity relationships, and pharmacological properties of the GHRP family. It remains an essential reference for researchers new to the field of synthetic GH secretagogues.

Handling, Reconstitution & Storage

Proper handling is essential to maintain GHRP-6 structural integrity and bioactivity. The following guidelines reflect standard laboratory practices for research peptides:

Lyophilized Storage. Store the lyophilized powder at -20°C in a desiccated environment, protected from light and moisture. Lyophilized GHRP-6 is stable for up to 24 months under these conditions. Avoid repeated freeze-thaw cycles, as condensation can introduce moisture and promote peptide aggregation or degradation.

Reconstitution. GHRP-6 is freely soluble in sterile water, 0.9% saline, or phosphate-buffered saline (PBS). For most research applications, reconstitution at 1–5 mg/mL is recommended. Add the solvent slowly to the vial wall, allowing it to run down gently onto the lyophilized cake. Swirl gently to dissolve; avoid vigorous vortexing or shaking, which can cause mechanical denaturation and aggregation of the peptide. Do not introduce air bubbles by drawing solvent in and out of the pipette tip unnecessarily.

Reconstituted Solution Storage. Reconstituted GHRP-6 should be stored at 4°C for short-term use (up to 14 days). For longer-term storage, aliquot the solution into single-use volumes, freeze at -20°C, and thaw each aliquot only once immediately before use. For research protocols requiring maximum peptide stability, the addition of 0.1% bovine serum albumin (BSA) as a carrier protein can reduce adsorptive losses to container surfaces, though this may not be compatible with all experimental designs.

pH Considerations. GHRP-6 is stable across a pH range of approximately 4.0–7.5. Reconstitution in acidic solutions (pH < 3.0) or alkaline solutions (pH > 9.0) should be avoided, as extreme pH conditions can promote deamidation, oxidation of tryptophan residues, and peptide bond hydrolysis.

Aseptic Technique. All reconstitution and handling steps should be performed under aseptic conditions in a biosafety cabinet or laminar flow hood. Use sterile solvents, sterile syringes or pipette tips, and sterile sealed vials. For in vivo studies requiring repeated sampling from a stock vial, filtration through a 0.22 μm sterile syringe filter is recommended to maintain solution sterility. Discard any solution that shows visible turbidity, particulate formation, or microbial contamination.

Safety & Laboratory Precautions

GHRP-6 is classified as a research chemical and must be handled with appropriate laboratory safety precautions. Key safety considerations include:

Personal Protective Equipment (PPE). Always wear appropriate PPE when handling GHRP-6, including nitrile gloves, a laboratory coat, and safety glasses or goggles. For procedures that may generate peptide dust or aerosols (such as weighing lyophilized powder), a properly fitted N95 respirator or work in a fume hood is recommended.

Institutional Approval. All research involving GHRP-6 must be conducted under protocols approved by the relevant institutional review bodies, including Institutional Animal Care and Use Committees (IACUC) for in vivo studies and Institutional Biosafety Committees (IBC) where applicable. Researchers are responsible for compliance with all institutional, local, state, and federal regulations.

Toxicity Profile. In published preclinical toxicology studies, GHRP-6 has demonstrated a favorable safety profile at research-relevant concentrations. No mutagenic or genotoxic effects have been reported in standard Ames and chromosomal aberration assays. However, comprehensive toxicological characterization at high doses and over extended exposure periods remains incomplete. Researchers should conduct their own toxicological assessments appropriate to their specific experimental protocols.

Disposal. Dispose of unused GHRP-6, reconstituted solutions, and contaminated materials in accordance with institutional guidelines for chemical and biological waste. GHRP-6 should not be discharged into water systems or disposed of in general laboratory trash without appropriate deactivation.

Accidental Exposure. In the event of skin contact, wash the affected area thoroughly with soap and water. For eye exposure, flush with copious amounts of water for at least 15 minutes and seek medical evaluation. If inhalation of peptide dust occurs, move to fresh air and seek medical attention if respiratory symptoms develop. Maintain current Safety Data Sheet (SDS) documentation in the laboratory.

Frequently Asked Questions

Q: What is the difference between GHRP-6 and GHRP-2?
A: GHRP-6 and GHRP-2 are both synthetic hexapeptide ghrelin mimetics that stimulate GH release through GHS-R1a agonism. However, they differ in amino acid sequence, receptor binding affinity, and pharmacological profile. GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) contains two D-amino acids and demonstrates a balanced profile of GH release and appetite stimulation. GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂) is generally characterized by greater GH-releasing potency per unit mass and comparatively less pronounced effects on appetite and gastric motility. Researchers should select the GHS variant most appropriate for their specific study endpoints.

Q: Can GHRP-6 be used in combination with other secretagogues?
A: In research settings, GHRP-6 is frequently studied in combination with GHRH or GHRH analogs to exploit the well-documented synergistic interaction between the GHS and GHRH signaling pathways. The simultaneous activation of G_q-coupled (GHRP-6/GHS-R1a) and G_s-coupled (GHRH/GHRH-R) signaling cascades in pituitary somatotrophs produces GH release responses far exceeding additive expectations. Researchers designing co-administration protocols should carefully consider the pharmacokinetic properties of both agents and validate their methodology in pilot experiments.

Q: How does GHRP-6 compare to ipamorelin?
A: Ipamorelin is a pentapeptide GHS with greater selectivity for GH release relative to other GHS-R1a-mediated effects, including significantly reduced appetite stimulation and minimal effects on prolactin and cortisol. GHRP-6, by contrast, exhibits a broader pharmacological footprint that includes pronounced orexigenic and gastric prokinetic effects in addition to GH stimulation. Researchers interested specifically in GH/IGF-1 axis effects with minimal confounding variables may prefer ipamorelin, while those investigating appetite regulation, energy homeostasis, or gastrointestinal physiology alongside GH secretion may find GHRP-6 more informative.

Q: What animal models are most commonly used with GHRP-6?
A: GHRP-6 has been studied in a wide range of preclinical animal models. Rodent models (rats and mice) are most common for mechanistic studies, including GH release assays, feeding behavior experiments, and molecular signaling investigations. Large-animal models, including swine and ovine species, have been used to study the effects of GHRP-6 on GH pulsatility and body composition in settings more anatomically and physiologically relevant to human biology. Researchers should verify that the GHS-R1a of their chosen species has appropriate affinity for GHRP-6, as receptor pharmacology can vary across species.

Q: What are the key stability considerations for reconstituted GHRP-6?
A: Reconstituted GHRP-6 is most stable at refrigerated temperatures (4°C) in sterile, neutral-pH buffer. The primary degradation pathways include oxidation of tryptophan residues (accelerated by exposure to light and dissolved oxygen), deamidation at asparagine/glutamine residues if present, and peptide bond hydrolysis under acidic or alkaline conditions. For research protocols extending beyond 14 days, aliquot the reconstituted solution, freeze at -20°C, and use each aliquot only once after thawing. Avoid repeated freezing and thawing of the same aliquot. The addition of 0.1% BSA can reduce adsorptive losses to polypropylene or glass surfaces. Record the date of reconstitution and storage conditions in the laboratory notebook.

References

1. Bowers CY. Growth hormone-releasing peptides and their analogues. Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9141532.
2. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8940206.
3. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1995;128(4):2027-2035. PMID: 7593426.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470.
5. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. PMID: 8954023.
6. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85(12):4908-4911. PMID: 11134161.
7. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141(11):4325-4328. PMID: 11089570.
8. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85(2):495-522. PMID: 15788704.